Another consequence of our study is that therapeutic approaches for human tauopathies, focus in to evaluate the effectiveness of small interfering RNAs delivered to suppress human tau expression or other anti-tau therapies for Alzheimer’s disease currently in development [57], could potentially have unexpected off-target effects that should be considered. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.